Mydecine Innovations Group Inc C.MYCO

Alternate Symbol(s): MYCOF

Mydecine Innovations Group Inc. is a Canada-based biotechnology company. The Company is engaged in developing medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company conducts research and development on second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The Company has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The Company is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.

CSE:MYCO - Post by User

Mydecine Innovations Group Inc

Bullboard Posts

Post by Yoshitoshion Nov 21, 2016 12:57pm

138 Views

Post# 25490295

After the Arrangement

Following completion of the Arrangement, there will be two separate operating companies: New Age Farm Inc. and NHS Industries Ltd., each with its own assets, liabilities and separate business operations.

New Age Farm will continue to operate the properties in Washington State and NHS will be responsible for operations at the Langley location. Shareholders of New Age Farm will now hold an interest in two operating agribusinesses and will benefit from the Company’s plan to list NHS Industries Ltd. on a stock exchange that will ultimately provide shareholders the opportunity to realize the benefit of additional liquidity in their investments.

Bullboard Posts

Global Tungsten Market and Supply Security